Nimbus Therapeutics

Thank you David Wild, and the In Vivo team, for spotlighting the pivotal role of disciplined portfolio management in drug development. At Nimbus Therapeutics, we've learned that innovation isn’t just about pursuing every opportunity—it’s about making tough, strategic choices: knowing when to pivot, redirect, or even stop. As I shared in the article, "Like your program, but love the portfolio." This philosophy has been central to our success and resilience as a company. By focusing our resources where they matter most, we’ve unlocked meaningful opportunities. Redirecting efforts to our #TYK2 inhibitor program led to our impactful collaboration with Takeda, while strategically pausing our #AMPK program paved the way for our partnership with Eli Lilly and Company. You can read the full article in Citeline Commercial below:

'Like your program, but love the portfolio' — this guiding principle at Nimbus reflects our commitment to strategic decision-making in drug development. Our Chief Business Officer Abbas Kazimi recently spoke with David Wild at In Vivo about the strategic value of "failing fast" in drug development. By identifying unsuccessful candidates early and decisively pivoting resources to higher-probability programs, we've built a strong portfolio and established valuable partnerships, including our landmark deal with Takeda and ongoing collaboration with Eli Lilly and Company. Abbas shared insights on how strategic portfolio management and decisive decision-making create value for scientists, investors, partners, and ultimately, patients. https://lnkd.in/eQkft46X

Next month, just ahead of the J.P. Morgan Healthcare Conference, our CEO Jeb Keiper will join a distinguished panel at the Longwood Healthcare Leaders San Francisco CEO event. The panel, “Impact & Importance of Company Culture” brings together industry leaders for an insightful discussion on Saturday January 11. Learn more: https://lnkd.in/esNkzCWY 

We’re honored to once again be named as one of Boston Globe Media’s ‘Top Places to Work’ for 2024. At Nimbus, our vibrant culture defines who we are. We’re driven by innovation, fueled by collaboration, and united in our mission to make breakthrough medicines for patients. This repeated honor reflects the passion and commitment of every team member who makes Nimbus such a special place to work. Read the official #TopPlacesToWork announcement: https://bit.ly/49pEvBd #WorkBoston

From neuroscience to oncology, coincidences to catalysts! Thrilled to share this fascinating conversation between our SVP, TA Head, Oncology, Anita Scheuber, MD, PhD and Charles Spence on the "A Dose of Reality" podcast.  Discover how Anita navigated from the ICU to AI-driven drug discovery at Nimbus - bringing a unique perspective to #drugdevelopment. She shares candid insights about co-founding a biotech startup, and why she believes leadership in pharma is truly a partnership. Listen to the full podcast: https://lnkd.in/eAg_iBtu 

Earlier this month, our #Nimbi had the pleasure of participating in another volunteer effort at the Pine Street Inn, decorating Halloween cookies to help spread some holiday spirit. Find out how you can support the Pine Street Inn’s efforts to help the homeless in New England here: https://lnkd.in/dpRVp_x

November spotlights critical health challenges: #LungCancer, #PancreaticCancer, and #GastricCancer awareness months. At Nimbus, we're advancing breakthrough medicines through precision small molecule #drugdiscovery to reach patients who need them most. Learn more about each disease and how to find effective screenings, treatments and support from the American Association for Cancer Research below: Lung Cancer: https://bit.ly/3JdZTeH Pancreatic Cancer: https://bit.ly/3MppS6q Gastric Cancer: https://bit.ly/3ARBdK2

Our SVP, TA Head, Oncology Anita Scheuber, MD, PhD sat down with Megan Hollasch at OncLive to discuss our novel HPK1 inhibitor ND)-101150, its mechanism of action, and clinical observations from our Phase 1/2 trial. Read the full article here: https://lnkd.in/eKJt8wfp 

This week, our #BusinessOps team connected courtside at TD Garden for Celtics vs Hawks. Win or lose, nothing beats team bonding at a home game! A great evening with our #Nimbi crew.

Hot off the press – excited to reshare this new preprint from the Polaris - Benchmarks for methods that matter consortium addressing replicability challenges in ML-based #drugdiscovery!    Experts from leading pharma and biotech companies propose clear guidelines for evaluating ML methods, an essential step toward bridging the gap between perceived progress and real-world impact. We’re proud that our VP of Computational Chemistry and Structural Biology, Daniel Price, is a co-author of this important work!  https://lnkd.in/g6w78h9W   #DrugDiscovery #MachineLearning